Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | FGFR3 - TACC3 |
Therapy | AZ8010 |
Indication/Tumor Type | urinary bladder cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 - TACC3 | urinary bladder cancer | sensitive | AZ8010 | Preclinical | Actionable | In a preclinical study, AZ12908010 (AZ8010) induced cell cycle arrest and inhibited proliferation of urothelial cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 22869148, PMID: 23175443). | 22869148 23175443 |
PubMed Id | Reference Title | Details |
---|---|---|
(22869148) | Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. | Full reference... |
(23175443) | Oncogenic FGFR3 gene fusions in bladder cancer. | Full reference... |